ClinicalTrials.gg
CompletedNCT06350474SIMPLIFY-DNUpdated Nov 26, 2024Results posted

Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study

An interventional study of Discontinuation of dornase alfa (Dnase) and Continuation of dornase alfa (Dnase) in Cystic Fibrosis, sponsored by Nicole Hamblett. Completed at 81 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.

Sponsored by Nicole Hamblett · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled Aug 2020, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
477
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Enrollment
18th of 517
477 · median 36
Started
2020
with 33 others
No phase
155 of 717
17 open now
Registered
665th of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 18th largest by enrollment of the 517 interventional ones that give a count, is one of 34 that started in 2020, is one of 155 with no phase, and was the 665th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

80 more — sign in →

All 85 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

Despite the increasingly common use of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies in treating cystic fibrosis (CF), it is still largely unknown whether or not other chronic therapies can be safely stopped. This SIMPLIFY sub-study is being done to test whether or not it is safe to stop taking dornase alfa (Dnase) in those people that are also taking elexacaftor/tezacaftor/ivacaftor (ETI).

ETI is a combination CFTR modulator therapy that was approved by the Food and Drug Administration for people with CF who have at least one F508del mutation. The three drugs that make up ETI work together to allow many more chloride ions to move into and out of the cells, improving the balance of salt and water in the lungs. These changes result in better clearance of mucus from the lungs and improvements in lung function.

Dornase alfa (Dnase) also improves clearance of mucus from the lungs to support lung function and has been available to people with CF for many years. Dnase is considered to be relatively burdensome and it is not known whether Dnase can improve or maintain lung function above what is already gained through ETI use.

The goal of this SIMPLIFY sub-study is to get information about whether or not it is safe to stop Dnase by testing if there is a change in lung function in participants with cystic fibrosis (CF) who are assigned to stop taking Dnase as compared to those who are assigned to keep taking Dnase while continuing to take ETI.

This is a sub study of master protocol SIMPLIFY-IP-19, NCT04378153.

The sub study investigating the impact of discontinuing and continuing hypertonic saline is registered under NCT06350461.

Read the detailed description

This SIMPLIFY sub-study (Dornase Alfa (Dnase) Trial) is designed to evaluate the effects of discontinuing Dnase in people with cystic fibrosis (CF) age 12 and older currently taking the highly effective modulator elexacaftor/tezacaftor/ivacaftor (ETI). This is an open label two-arm randomized non-inferiority trial consisting of a 2-week screening period, randomization to continue or discontinue dornase alfa, followed by a 6-week study period. Participants at trial entry will be randomized 1:1 to either continue or discontinue their Dnase therapy.

Clinical outcomes (forced expiratory volume in 1 second [FEV1], antibiotic use, pulmonary exacerbations, and patient reported outcomes), safety (adverse events) and patient reported outcomes to evaluate respiratory symptoms and the participant's perception of how stopping Dnase would impact their daily life will be evaluated in all subjects. Additionally, a subset of participants at selected study sites will participate in Multiple Breath Washout (MBW) to evaluate changes in lung clearance index (LCI).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

Keywords

  • Cystic Fibrosis
  • CF
  • Withdrawal
  • ETI
  • dornase alfa
  • discontinue
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of CF.
  • Age ≥ 12 years at the Screening Visit.
  • (FEV1) ≥ 70 % predicted at the Screening Visit if \< 18 years old, and ≥ 60 % predicted at Screening Visit if ≥ 18 years old.
  • Clinically stable with no significant changes in health status within the 7 days prior to and including the Screening Visit.
  • Current treatment with elexacaftor/tezacaftor/ivacaftor (ETI) for at least the 90 days prior to and including the Screening Visit and willing to continue daily use for the duration of the study.
  • Currently taking dornase alfa for at least the 90 days prior to and including the Screening Visit and willing to continue daily use for the 2-week screening period.

Exclusion criteria

Exclusion Criteria:

  • Active smoking or vaping.
  • Use of an drug within 28 days prior to and including the Screening Visit.
  • Changes to chronic therapy (e.g., ibuprofen, azithromycin, inhaled tobramycin, aztreonam lysine) within 28 days prior to and including the Screening Visit. This includes new airway clearance routines.
  • Acute use of antibiotics (oral, inhaled or IV) or acute use of systemic for respiratory tract symptoms within 7 days prior to and including the Screening Visit.
  • Chronic use of systemic corticosteroids at a dose equivalent to ≥ 10mg per day of prednisone within 28 days prior to and including the Screening Visit.
  • Antibiotic treatment for nontuberculous mycobacteria (NTM) within 28 days prior to and including the Screening Visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
477 participants (actual)

Study arms

  • Experimental
    Dnase - Discontinue

    Discontinuation of current dornase alfa (dnase) therapy

    Other: Discontinuation of dornase alfa (Dnase)

  • Active comparator
    Dnase - Continue

    Continuation of current dornase alfa (dnase) therapy

    Other: Continuation of dornase alfa (Dnase)

Interventions

  • OtherDiscontinuation of dornase alfa (Dnase)

    Discontinuation of current dornase alfa (Dnase) therapy during 6-week study period.

  • OtherContinuation of dornase alfa (Dnase)

    Continuation of current dornase alfa (dnase) therapy during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily)

06

What researchers measure

Primary outcomes

  1. Absolute Change in FEV1 % Predicted From Week 0 to Week 6

    Non-Inferiority statistical testing compared difference between study arms (discontinue - continue) in the absolute change in FEV1 % predicted from Week 0 to Week 6.

    Time frame: Week 0 to Week 6

Secondary outcomes

  1. Absolute Change in LCI 2.5 From Baseline to Week 6

    Statistical testing compared difference between study arms (discontinue - continue) in the absolute change in LCI 2.5 (Lung Clearance Index) from Baseline (Week 0, if available, or else Week -2) to Week 6. LCI 2.5 is the number of times the volume in the lungs needs to turn over to expel an inert gas. A higher value of LCI 2.5 indicates poorer lung function.

    Time frame: Baseline (Week 0 or Week -2) to Week 6

  2. Absolute Change in Respiratory Symptoms, as Measured by the CF Respiratory Symptoms Diary-Chronic Respiratory Infection Symptom Severity Score (CRISS) From Week 0 to Week 6

    Statistical testing compared the difference between study arms (discontinue - continue) in the absolute change in respiratory symptoms, as measured by the CF Respiratory Symptoms Diary-Chronic Respiratory Infection Symptom Severity Score (CRISS) from Week 0 to Week 6. The Cystic Fibrosis Respiratory Symptoms Daily Diary (CFRSD) asks a participant to state the extent of their 8 respiratory symptoms: difficulty breathing, feverishness, tiredness, chills or sweats, coughing, coughing up mucus, tightness in the chest and wheezing. Each respiratory symptom is assigned a score from 0-4 based on the response, with zero corresponding to the absence of the symptom and four corresponding to symptom being present 'a great deal' or 'extremely'. A summed score (range from 0-24) is calculated for each participant and converted to a final score with a range of 0 to 100 where the lowest scores indicate improvement of symptoms. Calculation of a score requires responses for at least 7 out of 8 symptoms

    Time frame: Week 0 to Week 6

  3. Absolute Change in Respiratory Symptoms, as Measured by CFQ-R Respiratory Domain From Week 0 to Week 6

    Statistical testing compared the difference between study arms (discontinue - continue) in the absolute change in respiratory symptoms, as measured by the Cystic Fibrosis Questionnaire-Revised Respiratory Domain Score from Week 0 to Week 6. The Cystic Fibrosis Questionnaire - Revised asks participants 6 questions related to respiratory symptoms which are each assigned a score 1-4. The Respiratory Domain Scaled Score is calculated as follows: 100\*\[{sum of responses}/{number of responses}-1\]/3 only if number of responses ≥ 3; otherwise the score is set to missing. The scaled score ranges from 0 to 100 where higher scores indicate improvement of symptoms.

    Time frame: Week 0 to Week 6

  4. Absolute Change in FEV1 % Predicted From Week -2 to Week 0

    Statistical testing compared the difference between study arms (discontinue - continue) in the absolute change in FEV1 % predicted from Week -2 to Week 0.

    Time frame: Week -2 to Week 0

  5. Absolute Change in FEV1 % Predicted From Week 0 to Week 2

    Statistical testing compared the difference between study arms (discontinue - continue) in the absolute change in FEV1 % predicted from Week 0 to Week 2.

    Time frame: Week 0 to Week 2

  6. Number and Percent of Participants Initiating Acute Antibiotics From Week 0 to Week 6

    Difference between study arms (discontinue - continue) in the percent of subjects initiating acute oral, inhaled or intravenous antibiotics from Week 0 to Week 6. Includes antibiotics initiated for respiratory indications; excludes those taken as part of a chronic cycled regimen or for a UTI, skin infection, etc.

    Time frame: Week 0 to Week 6

  7. Number and Percent of Participants Hospitalized From Week 0 to Week 6

    Statistical testing compared the difference between study arms (discontinue - continue) in the percent of subjects hospitalized from Week 0 to Week 6.

    Time frame: Week 0 to Week 6

  8. Number and Percent of Participants Experiencing Pulmonary Exacerbations From Week 0 to Week 6

    Statistical testing compared the difference between study arms (discontinue - continue) in the percent of subjects experiencing a pulmonary exacerbation from Week 0 to Week 6. Pulmonary exacerbations defined using Fuchs criteria.

    Time frame: Week 0 to Week 6

  9. Number and Percent of Participants Experiencing Adverse Events (AEs) From Week 0 to Week 6

    Statistical testing compared the difference between study arms (discontinue - continue) in the percent of participants with at least one AE from Week 0 to Week 6. Includes serious and non-serious AEs.

    Time frame: Week 0 to Week 6

  10. Rate of Adverse Events (AEs) From Week 0 to Week 6 Therapy Arms

    Statistical testing compared the compared the rate of AE occurrence (number of events divided by total follow-up weeks in each arm) between study arms from Week 0 to Week 6. Includes serious and non-serious AEs.

    Time frame: Week 0 to Week 6

  11. Number and Percent of Participants With Temporary or Permanent Changes From Assigned Therapy Regimen Due to Adverse Event From Week 0 to Week 6

    Statistical testing compared the difference between study arms (discontinue - continue) in the percent of subjects temporarily or permanently changing their assigned therapy regimen due to an adverse event Week 0 to Week 6

    Time frame: Week 0 to Week 6

07

Results

Posted Nov 26, 2024

Participant flow

Participant flow — Overall Study
MilestoneDnase - DiscontinueDnase - Continue
Started240237
Completed238236
Not completed21

Outcome measures

PrimaryAbsolute Change in FEV1 % Predicted From Week 0 to Week 6

Non-Inferiority statistical testing compared difference between study arms (discontinue - continue) in the absolute change in FEV1 % predicted from Week 0 to Week 6.

Time frame:
Week 0 to Week 6
Reported as:
Mean · FEV1 % predicted
Absolute Change in FEV1 % Predicted From Week 0 to Week 6
FEV1 % predictedDnase - DiscontinueDnase - Continue
Absolute Change in FEV1 % Predicted From Week 0 to Week 60.2 ± 3.69-0.2 ± 4.37
Statistical analysis
  • Dnase - Discontinue vs Dnase - Continue · ANOVA · p = <0.0001 (One-sided test for non-inferiority.) · Mean difference (final values): 0.346 · 95% CI -0.5 to 1.1Direction of difference is Discontinue - Continue.
SecondaryAbsolute Change in LCI 2.5 From Baseline to Week 6

Statistical testing compared difference between study arms (discontinue - continue) in the absolute change in LCI 2.5 (Lung Clearance Index) from Baseline (Week 0, if available, or else Week -2) to Week 6. LCI 2.5 is the number of times the volume in the lungs needs to turn over to expel an inert gas. A higher value of LCI 2.5 indicates poorer lung function.

Time frame:
Baseline (Week 0 or Week -2) to Week 6
Reported as:
Mean · number of lung volume turnovers
Absolute Change in LCI 2.5 From Baseline to Week 6
number of lung volume turnoversDnase - DiscontinueDnase - Continue
Absolute Change in LCI 2.5 From Baseline to Week 6-0.1 ± 0.630.0 ± 0.56
Statistical analysis
  • Dnase - Discontinue vs Dnase - Continue · ANOVA · p = 0.414 · Mean difference (final values): -0.11 · 95% CI -0.4 to 0.2Direction of difference is Discontinue - Continue.
SecondaryAbsolute Change in Respiratory Symptoms, as Measured by the CF Respiratory Symptoms Diary-Chronic Respiratory Infection Symptom Severity Score (CRISS) From Week 0 to Week 6

Statistical testing compared the difference between study arms (discontinue - continue) in the absolute change in respiratory symptoms, as measured by the CF Respiratory Symptoms Diary-Chronic Respiratory Infection Symptom Severity Score (CRISS) from Week 0 to Week 6. The Cystic Fibrosis Respiratory Symptoms Daily Diary (CFRSD) asks a participant to state the extent of their 8 respiratory symptoms: difficulty breathing, feverishness, tiredness, chills or sweats, coughing, coughing up mucus, tightness in the chest and wheezing. Each respiratory symptom is assigned a score from 0-4 based on the response, with zero corresponding to the absence of the symptom and four corresponding to symptom being present 'a great deal' or 'extremely'. A summed score (range from 0-24) is calculated for each participant and converted to a final score with a range of 0 to 100 where the lowest scores indicate improvement of symptoms. Calculation of a score requires responses for at least 7 out of 8 symptoms

Time frame:
Week 0 to Week 6
Reported as:
Mean · score on a scale
Absolute Change in Respiratory Symptoms, as Measured by the CF Respiratory Symptoms Diary-Chronic Respiratory Infection Symptom Severity Score (CRISS) From Week 0 to Week 6
score on a scaleDnase - DiscontinueDnase - Continue
Absolute Change in Respiratory Symptoms, as Measured by the CF Respiratory Symptoms Diary-Chronic Respiratory Infection Symptom Severity Score (CRISS) From Week 0 to Week 6-0.1 ± 9.49-1.1 ± 10.21
Statistical analysis
  • Dnase - Discontinue vs Dnase - Continue · ANOVA · p = 0.241 · Mean difference (final values): 0.95 · 95% CI -1.0 to 2.9Direction of difference is Discontinue - Continue.
SecondaryAbsolute Change in Respiratory Symptoms, as Measured by CFQ-R Respiratory Domain From Week 0 to Week 6

Statistical testing compared the difference between study arms (discontinue - continue) in the absolute change in respiratory symptoms, as measured by the Cystic Fibrosis Questionnaire-Revised Respiratory Domain Score from Week 0 to Week 6. The Cystic Fibrosis Questionnaire - Revised asks participants 6 questions related to respiratory symptoms which are each assigned a score 1-4. The Respiratory Domain Scaled Score is calculated as follows: 100\*\[{sum of responses}/{number of responses}-1\]/3 only if number of responses ≥ 3; otherwise the score is set to missing. The scaled score ranges from 0 to 100 where higher scores indicate improvement of symptoms.

Time frame:
Week 0 to Week 6
Reported as:
Mean · score on a scale
Absolute Change in Respiratory Symptoms, as Measured by CFQ-R Respiratory Domain From Week 0 to Week 6
score on a scaleDnase - DiscontinueDnase - Continue
Absolute Change in Respiratory Symptoms, as Measured by CFQ-R Respiratory Domain From Week 0 to Week 6-0.9 ± 6.230.0 ± 8.85
Statistical analysis
  • Dnase - Discontinue vs Dnase - Continue · ANOVA · p = 0.233 · Mean difference (final values): -0.92 · 95% CI -2.5 to 0.6Direction of difference is Discontinue - Continue.
SecondaryAbsolute Change in FEV1 % Predicted From Week -2 to Week 0

Statistical testing compared the difference between study arms (discontinue - continue) in the absolute change in FEV1 % predicted from Week -2 to Week 0.

Time frame:
Week -2 to Week 0
Reported as:
Mean · FEV1 % predicted
Absolute Change in FEV1 % Predicted From Week -2 to Week 0
FEV1 % predictedDnase - DiscontinueDnase - Continue
Absolute Change in FEV1 % Predicted From Week -2 to Week 00.2 ± 3.110.0 ± 3.79
Statistical analysis
  • Dnase - Discontinue vs Dnase - Continue · t-test, 2 sided · p = 0.42 · Mean difference (final values): 0.28 · 95% CI -0.4 to 0.97Direction of difference is Discontinue - Continue.
SecondaryAbsolute Change in FEV1 % Predicted From Week 0 to Week 2

Statistical testing compared the difference between study arms (discontinue - continue) in the absolute change in FEV1 % predicted from Week 0 to Week 2.

Time frame:
Week 0 to Week 2
Reported as:
Mean · FEV1 % predicted
Absolute Change in FEV1 % Predicted From Week 0 to Week 2
FEV1 % predictedDnase - DiscontinueDnase - Continue
Absolute Change in FEV1 % Predicted From Week 0 to Week 2-0.1 ± 3.670.1 ± 3.96
Statistical analysis
  • Dnase - Discontinue vs Dnase - Continue · t-test, 2 sided · p = 0.69 · Mean difference (final values): -0.15 · 95% CI -0.92 to 0.61Direction of difference is Discontinue - Continue.
SecondaryNumber and Percent of Participants Initiating Acute Antibiotics From Week 0 to Week 6

Difference between study arms (discontinue - continue) in the percent of subjects initiating acute oral, inhaled or intravenous antibiotics from Week 0 to Week 6. Includes antibiotics initiated for respiratory indications; excludes those taken as part of a chronic cycled regimen or for a UTI, skin infection, etc.

Time frame:
Week 0 to Week 6
Reported as:
Count of participants · Participants
Number and Percent of Participants Initiating Acute Antibiotics From Week 0 to Week 6
ParticipantsDnase - DiscontinueDnase - Continue
Number and Percent of Participants Initiating Acute Antibiotics From Week 0 to Week 6148
Statistical analysis
  • Dnase - Discontinue vs Dnase - Continue · Fisher Exact · p = 0.275 · Difference in % participants: 2.5 · 95% CI -1.5 to 6.5Confidence interval calculated using the Newcombe-Wilson method without continuity correction. Direction of difference is Discontinue - Continue.
SecondaryNumber and Percent of Participants Hospitalized From Week 0 to Week 6

Statistical testing compared the difference between study arms (discontinue - continue) in the percent of subjects hospitalized from Week 0 to Week 6.

Time frame:
Week 0 to Week 6
Reported as:
Count of participants · Participants
Number and Percent of Participants Hospitalized From Week 0 to Week 6
ParticipantsDnase - DiscontinueDnase - Continue
Number and Percent of Participants Hospitalized From Week 0 to Week 600
SecondaryNumber and Percent of Participants Experiencing Pulmonary Exacerbations From Week 0 to Week 6

Statistical testing compared the difference between study arms (discontinue - continue) in the percent of subjects experiencing a pulmonary exacerbation from Week 0 to Week 6. Pulmonary exacerbations defined using Fuchs criteria.

Time frame:
Week 0 to Week 6
Reported as:
Count of participants · Participants
Number and Percent of Participants Experiencing Pulmonary Exacerbations From Week 0 to Week 6
ParticipantsDnase - DiscontinueDnase - Continue
Number and Percent of Participants Experiencing Pulmonary Exacerbations From Week 0 to Week 642
Statistical analysis
  • Dnase - Discontinue vs Dnase - Continue · Fisher Exact · p = 0.686 · Difference in % participants: 0.8 · 95% CI -1.6 to 3.4Confidence interval calculated using the Newcombe-Wilson method without continuity correction. Direction of difference is Discontinue - Continue.
SecondaryNumber and Percent of Participants Experiencing Adverse Events (AEs) From Week 0 to Week 6

Statistical testing compared the difference between study arms (discontinue - continue) in the percent of participants with at least one AE from Week 0 to Week 6. Includes serious and non-serious AEs.

Time frame:
Week 0 to Week 6
Reported as:
Count of participants · Participants
Number and Percent of Participants Experiencing Adverse Events (AEs) From Week 0 to Week 6
ParticipantsDnase - DiscontinueDnase - Continue
Number and Percent of Participants Experiencing Adverse Events (AEs) From Week 0 to Week 68955
Statistical analysis
  • Dnase - Discontinue vs Dnase - Continue · Fisher Exact · p = 0.0010 · Difference in % participants: 13.9 · 95% CI 5.6 to 21.8Confidence interval calculated using the Newcombe-Wilson method without continuity correction. Direction of difference is Discontinue - Continue.
SecondaryRate of Adverse Events (AEs) From Week 0 to Week 6 Therapy Arms

Statistical testing compared the compared the rate of AE occurrence (number of events divided by total follow-up weeks in each arm) between study arms from Week 0 to Week 6. Includes serious and non-serious AEs.

Time frame:
Week 0 to Week 6
Reported as:
Number · events per week
Rate of Adverse Events (AEs) From Week 0 to Week 6 Therapy Arms
events per weekDnase - DiscontinueDnase - Continue
Rate of Adverse Events (AEs) From Week 0 to Week 6 Therapy Arms0.1160.060
Statistical analysis
  • Dnase - Discontinue vs Dnase - Continue · Poisson Regression · p = <0.0001 · Rate ratio: 1.95 · 95% CI 1.51 to 2.53
SecondaryNumber and Percent of Participants With Temporary or Permanent Changes From Assigned Therapy Regimen Due to Adverse Event From Week 0 to Week 6

Statistical testing compared the difference between study arms (discontinue - continue) in the percent of subjects temporarily or permanently changing their assigned therapy regimen due to an adverse event Week 0 to Week 6

Time frame:
Week 0 to Week 6
Reported as:
Count of participants · Participants
Number and Percent of Participants With Temporary or Permanent Changes From Assigned Therapy Regimen Due to Adverse Event From Week 0 to Week 6
ParticipantsDnase - DiscontinueDnase - Continue
Number and Percent of Participants With Temporary or Permanent Changes From Assigned Therapy Regimen Due to Adverse Event From Week 0 to Week 672
Statistical analysis
  • Dnase - Discontinue vs Dnase - Continue · Fisher Exact · p = 0.1758 · Difference in % participants: 2.03 · 95% CI -0.6 to 5.0Confidence interval calculated using the Newcombe-Wilson method without continuity correction. Direction of difference is Discontinue - Continue.

Adverse events

Collected over From randomization (Week 0) up to last study visit (Week 6), i.e., 6 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dnase - Discontinue0/240 (0%)0/240 (0%)25/240 (10.4%)
Dnase - Continue0/237 (0%)0/237 (0%)14/237 (5.9%)
Most frequent other events
Most frequent other events
EventDnase - DiscontinueDnase - Continue
CoughRespiratory, thoracic and mediastinal disorders16/24010/237
Nasal congestionRespiratory, thoracic and mediastinal disorders11/2404/237

Baseline characteristics

Primary analyses were done on the per-protocol (PP) population.

Age, Continuous
Age, Continuous(years)Dnase - DiscontinueDnase - ContinueTotal
Mean22.1 ± 9.3923.7 ± 11.8322.9 ± 10.7
Age, Customized
Age, Customized(Participants)Dnase - DiscontinueDnase - ContinueTotal
Age Distribution (years) — >=12 to <188985174
Age Distribution (years) — >=18 to <24453681
Age Distribution (years) — >=24 to <30252752
Age Distribution (years) — >=30404585
Sex: Female, Male
Sex: Female, Male(Participants)Dnase - DiscontinueDnase - ContinueTotal
Female9897195
Male10196197
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dnase - DiscontinueDnase - ContinueTotal
Race — White192187379
Race — Black or African American134
Race — Asian011
Race — American Indian or Alaskan Native101
Race — Native Hawaiian or Other Pacific Islander000
Race — Other, More than One Race, or Unknown/Not Reported527
Cystic Fibrosis (CF) Genotype
Cystic Fibrosis (CF) Genotype(Participants)Dnase - DiscontinueDnase - ContinueTotal
F508del Homozygous105115220
F508del Heterozygous9073163
Other or Unknown459
Forced Expiratory Volume in 1 second (FEV1)
Forced Expiratory Volume in 1 second (FEV1)(liters)Dnase - DiscontinueDnase - ContinueTotal
Mean3.3 ± 0.883.3 ± 0.863.3 ± 0.87
FEV1 (% Predicted)
FEV1 (% Predicted)(percent predicted)Dnase - DiscontinueDnase - ContinueTotal
Mean96.8 ± 17.4097.0 ± 16.3596.9 ± 16.87
FEV1 (% Predicted) Distribution
FEV1 (% Predicted) Distribution(Participants)Dnase - DiscontinueDnase - ContinueTotal
<60134
>=60 to <70161026
>=70 to <90464894
>=90 to <100424284
>=1009490184

2 further baseline measures are reported on the registry.

08

Study locations

81 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Providence Alaska Medical Center
    Anchorage, Alaska 99508, United States
  • Tucson Cystic Fibrosis Center
    Tucson, Arizona 85724, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Miller Children's and Women's Hospital Long Beach
    Long Beach, California 90806, United States
  • CHOC Children's Hospital
    Orange, California 92868, United States
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • Rady Children's Hospital and Health Center at the University of California San Diego
    San Diego, California 92123, United States
  • University of California, San Francisco - Adult Center
    San Francisco, California 94143, United States
  • University of California, San Francisco - Peds Center
    San Francisco, California 94158, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Nemours Children's Clinic - Jacksonville
    Jacksonville, Florida 32207, United States
  • Central Florida Pulmonary Group
    Orlando, Florida 32803, United States
  • The Nemours Children's Clinic - Orlando
    Orlando, Florida 32827, United States
  • Nemours Children's Clinic - Pensacola
    Pensacola, Florida 32514, United States
  • All Children's Hospital
    Saint Petersburg, Florida 33701, United States
  • Tampa General Hospital
    Tampa, Florida 33606, United States
  • Emory University
    Atlanta, Georgia 30324, United States
  • Saint Luke's Cystic Fibrosis Center of Idaho
    Boise, Idaho 83702, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • OSF Saint Francis Medical Center
    Peoria, Illinois 61637, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Kentucky
    Lexington, Kentucky 40506, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Tulane University
    Metairie, Louisiana 70001, United States
  • Maine Medical Partners Pediatric Specialty Care
    Portland, Maine 04102, United States
  • John Hopkins Hospital
    Baltimore, Maryland 21205, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • University of Michigan, Michigan Medicine
    Ann Arbor, Michigan 48109, United States
  • Wayne State University Harper University Hospital
    Detroit, Michigan 48201, United States
  • Corewell Health Helen DeVos
    Grand Rapids, Michigan 49546, United States
  • Children's Hospitals and Clinics of Minnesota
    Minneapolis, Minnesota 55404, United States
  • The Minnesota Cystic Fibrosis Center
    Minneapolis, Minnesota 55455, United States
  • Children's Mercy Kansas City
    Kansas City, Missouri 64108, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Billings Clinic
    Billings, Montana 59101, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Monmouth Medical Center
    Eatontown, New Jersey 07724, United States
  • Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • Rutgers - Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08903, United States
  • Cohen Children's Medical Center of New York
    New Hyde Park, New York 11042, United States
  • Beth Israel Medical Center
    New York, New York 10003, United States
  • Lenox Hill Hospital Cystic Fibrosis Center
    New York, New York 10028, United States
  • Columbia University Cystic Fibrosis Program
    New York, New York 10032, United States
  • University of Rochester Medical Center Strong Memorial
    Rochester, New York 14642, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • New York Medical College at Westchester Medical Center
    Valhalla, New York 10595, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27517, United States
  • Atrium Health Wake Forest Baptist
    Winston-Salem, North Carolina 27157, United States
  • Children's Hospital Medical Center of Akron
    Akron, Ohio 44308, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44146, United States
  • Cleveland Clinic Cystic Fibrosis Program
    Cleveland, Ohio 44195, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Dayton Children's Hospital
    Dayton, Ohio 45404, United States
  • Oregon Health & Sciences University
    Portland, Oregon 97239, United States
  • Hershey Medical Center Pennsylvania State University
    Hershey, Pennsylvania 17033, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15224, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Dell Children's Medical Center of Central Texas
    Austin, Texas 78723, United States
  • University of Texas Southwestern / Children's Health
    Dallas, Texas 75207, United States
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76104, United States
  • University of Texas Health Center at Tyler
    Tyler, Texas 75708, United States
  • Primary Children's Cystic Fibrosis Center
    Salt Lake City, Utah 84113, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
  • University of Virginia
    Charlottesville, Virginia 22904, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23219, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Providence Medical Group, Cystic Fibrosis Center
    Spokane, Washington 99204, United States
  • West Virginia University - Morgantown
    Morgantown, West Virginia 26506, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Children's Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Froedtert & Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Jul 2022, 22 months.

Results were first posted in Nov 2024, 2 years 4 months after primary completion.

Of 214 non-industry interventional studies with no phase under Cystic Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's 22 months is close to that.

Counting every sponsor, half of 229 studies reached it within 24 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2024
First posted
Apr 5, 2024
StartActual
Aug 25, 2020
Primary completionActual
Jul 11, 2022
CompletionActual
Jul 11, 2022
Results first posted
Nov 26, 2024
Last update
Nov 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06350474
Lead sponsor
Nicole Hamblett
Collaborators
Cystic Fibrosis Foundation, Dartmouth-Hitchcock Medical Center, University of Washington
Responsible party
Nicole Hamblett (Professor of Pediatrics, Division of Pulmonary and Sleep Medicine, University of Washington School of Medicine Adjunct Professor, Biostatistics, University of Washington School of Medicine Co-Executive Director, Cystic Fibrosis Therapeutics Development, Seattle Children's Hospital) — Sponsor-investigator
First posted
Apr 5, 2024
Start date
Aug 25, 2020
Primary completion
Jul 11, 2022
Completion
Jul 11, 2022
Results posted
Nov 26, 2024
Last update
Nov 26, 2024

Study contacts

Nicole Mayer-Hamblett, PhD
principal investigator · University of Washington/Seattle Children's
Alex Gifford, MD, FCCP
principal investigator · Dartmouth-Hitchcock Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion